Adjuvant HoldingsADJUVANT HOLDINGS CO.,LTD.4929東証スタンダード化学FY ending Mar 2026, consolidated, J-GAAP
Adjuvant Holdings brought in ¥4.1B in revenue.
Out of every ¥100 of sales, about ¥3 is left as operating profit.
Revenue changed -7.7% from the prior year, and it swung back to an operating profit.
FY ending Mar 2024 → FY ending Mar 2025
FY ending Mar 2024 → FY ending Mar 2025
For every ¥100 Adjuvant Holdings sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
有価証券報告書-第37期(2025/03/21-2026/03/20)
EDINET (FSA Japan)
有価証券報告書-第36期(2024/03/21-2025/03/20)
EDINET (FSA Japan)
有価証券報告書-第35期(2023/03/21-2024/03/20)
EDINET (FSA Japan)
有価証券報告書-第34期(2022/03/21-2023/03/20)
EDINET (FSA Japan)
訂正有価証券報告書-第33期(令和3年3月21日-令和4年3月20日)
EDINET (FSA Japan)
有価証券報告書-第32期(令和2年3月21日-令和3年3月20日)
Extracted from XBRL: 46 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.